BRPI0409366A - compostos de pirimido - Google Patents

compostos de pirimido

Info

Publication number
BRPI0409366A
BRPI0409366A BRPI0409366-6A BRPI0409366A BRPI0409366A BR PI0409366 A BRPI0409366 A BR PI0409366A BR PI0409366 A BRPI0409366 A BR PI0409366A BR PI0409366 A BRPI0409366 A BR PI0409366A
Authority
BR
Brazil
Prior art keywords
compounds
pyrimidine compounds
kdr
colon
lung
Prior art date
Application number
BRPI0409366-6A
Other languages
English (en)
Inventor
Yi Chen
Apostolos Dermatakis
Jin-Jun Liu
Kin-Chun Luk
Christophe Michoud
Pamela Loreen Rossman
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0409366A publication Critical patent/BRPI0409366A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"COMPOSTOS DE PIRIMIDO". A presente invenção refere-se a novos compostos de pirimido da fórmula: que são inibidores seletivos das cinases KDR e FGFR. Esses compostos e seus sais farmaceuticamente aceitáveis são agentes antiproliferativos usados no tratamento ou controle de tumores sólidos, em particular, tumores de mama, cólon, pulmão e próstata. Também descritas são composições farmacêuticas contendo esses compostos e o uso para tratamento de câncer.
BRPI0409366-6A 2003-04-10 2004-04-01 compostos de pirimido BRPI0409366A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46169403P 2003-04-10 2003-04-10
PCT/EP2004/003447 WO2004089955A1 (en) 2003-04-10 2004-04-01 Pyrimido compounds

Publications (1)

Publication Number Publication Date
BRPI0409366A true BRPI0409366A (pt) 2006-04-25

Family

ID=33159829

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409366-6A BRPI0409366A (pt) 2003-04-10 2004-04-01 compostos de pirimido

Country Status (11)

Country Link
US (1) US7115740B2 (pt)
EP (1) EP1615928A1 (pt)
JP (1) JP2006522756A (pt)
KR (2) KR20050111636A (pt)
CN (1) CN100497339C (pt)
AU (1) AU2004228155A1 (pt)
BR (1) BRPI0409366A (pt)
CA (1) CA2521124A1 (pt)
MX (1) MXPA05010765A (pt)
RU (1) RU2350617C2 (pt)
WO (1) WO2004089955A1 (pt)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004260689B8 (en) 2003-07-29 2008-05-15 Irm Llc Compounds and compositions as protein kinase inhibitors
US20070287716A1 (en) * 2004-10-28 2007-12-13 Hu Essa H Pyrimidine and Quinoline Potentiators of Metabotropic Glutamate Receptors
BRPI0619052A2 (pt) * 2005-11-28 2011-09-20 Hoffmann La Roche compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de diacilglicerol aciltransferase, e seu uso
EP1981886B1 (en) 2006-01-31 2009-08-12 F.Hoffmann-La Roche Ag 7h-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
CA2745970A1 (en) 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivative
EP2376494A4 (en) * 2008-12-12 2012-07-11 Msd Kk DIHYDROPYRIMIDOPYRIMIDINDERIVATE
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8642834B2 (en) 2009-02-27 2014-02-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ,エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
TWI548621B (zh) * 2011-04-22 2016-09-11 標誌製藥公司 經取代之二胺基甲醯胺及二胺基甲腈嘧啶、其組合物、及以該等治療之方法
EP2727920B1 (en) 2011-07-29 2016-11-02 FUJIFILM Corporation 1,5-naphthyridine derivative or salt thereof
GB201204384D0 (en) 2012-03-13 2012-04-25 Univ Dundee Anti-flammatory agents
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
MY181020A (en) 2013-03-15 2020-12-16 Sanofi Sa Heteroaryl compounds and uses thereof
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
PH12015502383B1 (en) * 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
MA38393B1 (fr) 2014-03-13 2018-11-30 Sanofi Sa Composés hétéroaryle et utilisations associées
CA2954186A1 (en) 2014-07-21 2016-01-28 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
WO2016014551A1 (en) 2014-07-21 2016-01-28 Dana-Farber Cancer Institute, Inc. Macrocyclic kinase inhibitors and uses thereof
EP3177295A4 (en) 2014-08-08 2018-06-13 Dana Farber Cancer Institute, Inc. Uses of salt-inducible kinase (sik) inhibitors
WO2016027781A1 (ja) 2014-08-18 2016-02-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 単環ピリジン誘導体の塩およびその結晶
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CA2976790C (en) 2015-02-20 2024-02-27 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CN114984013A (zh) 2015-03-25 2022-09-02 国立癌症研究中心 胆管癌治疗剂
AU2016374441B2 (en) 2015-12-17 2021-10-21 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
AU2017291812B2 (en) * 2016-07-05 2023-12-14 Dana-Farber Cancer Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
WO2018053373A1 (en) 2016-09-16 2018-03-22 The General Hospital Corporation Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis
EP3589284A4 (en) 2017-02-28 2020-12-16 The General Hospital Corporation USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS
CN110809576B (zh) * 2017-03-03 2022-08-30 奥克兰联合服务有限公司 Fgfr激酶抑制剂和药物用途
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019029541A1 (zh) * 2017-08-08 2019-02-14 南京药捷安康生物科技有限公司 成纤维细胞生长因子受体抑制剂及其用途
CN109836427B (zh) * 2017-11-29 2022-04-15 暨南大学 嘧啶并嘧啶酮类化合物及其应用
BR112020017922A2 (pt) 2018-03-28 2020-12-22 Eisai R&D Management Co., Ltd. Agente terapêutico para carcinoma hepatocelular
KR102956194B1 (ko) 2018-05-04 2026-04-23 인사이트 코포레이션 Fgfr 억제제의 염
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
AU2019414446A1 (en) * 2018-12-27 2021-07-15 Les Laboratoires Servier Sas Aza-heterobicyclic inhibitors of MAT2A and methods of use for treating cancer
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
GB201908511D0 (en) 2019-06-13 2019-07-31 Adorx Therapeutics Ltd Hydroxamate compounds
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GB201915828D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915831D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為fgfr抑制劑之三環雜環
US20250129067A1 (en) 2021-11-08 2025-04-24 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2025109026A1 (en) 2023-11-21 2025-05-30 Intervet International B.V. Process for the preparation of 4-fluoro-3-methoxyaniline

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2949466A (en) * 1958-03-04 1960-08-16 Parke Davis & Co Pyrimidine compounds and means of producing the same
NL6704601A (pt) * 1966-04-06 1967-10-09
US4425346A (en) * 1980-08-01 1984-01-10 Smith And Nephew Associated Companies Limited Pharmaceutical compositions
JPS60226882A (ja) * 1984-04-24 1985-11-12 Nippon Zoki Pharmaceut Co Ltd 新規ピリミドピリミジン誘導体
AU7622698A (en) 1996-12-05 1998-06-29 Sugen, Inc. Use of indolinone compounds as modulators of protein kinases
DE69939168D1 (de) * 1998-05-26 2008-09-04 Warner Lambert Co Bicyclische pyrimidine und bicyclische 3,4-dihydropyrimidine als inhibitoren der zellvermehrung
PL347432A1 (en) * 1998-10-23 2002-04-08 Hoffmann La Roche Bicyclic nitrogen heterocycles
DE60033307T2 (de) * 1999-10-21 2007-07-12 F. Hoffmann-La Roche Ag Heteroalkylamino-substituierte bicyclische stickstoffheterocyclen als p38-proteinkinase-inhibitoren
ATE349447T1 (de) * 1999-10-21 2007-01-15 Hoffmann La Roche Alkylamino-substituierte bicyclische heterocyclen als p38 protein kinase inhibitoren
AR030053A1 (es) 2000-03-02 2003-08-13 Smithkline Beecham Corp 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas
KR100571339B1 (ko) 2000-08-31 2006-04-17 에프. 호프만-라 로슈 아게 세포증식 억제제로서의 7-옥소 피리도피리미딘
NZ534069A (en) 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
US7196090B2 (en) * 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
EP1556053A4 (en) * 2002-10-31 2006-04-19 Amgen Inc ANTI-INFLAMMATORY AGENTS

Also Published As

Publication number Publication date
CA2521124A1 (en) 2004-10-21
US20040204427A1 (en) 2004-10-14
CN1809569A (zh) 2006-07-26
RU2350617C2 (ru) 2009-03-27
CN100497339C (zh) 2009-06-10
WO2004089955A1 (en) 2004-10-21
KR100864393B1 (ko) 2008-10-20
US7115740B2 (en) 2006-10-03
AU2004228155A1 (en) 2004-10-21
MXPA05010765A (es) 2005-12-12
EP1615928A1 (en) 2006-01-18
KR20050111636A (ko) 2005-11-25
KR20070087053A (ko) 2007-08-27
JP2006522756A (ja) 2006-10-05
RU2005134686A (ru) 2006-07-27

Similar Documents

Publication Publication Date Title
BR0315912A (pt) Compostos pirimìdicos com atividade antiproliferativa (ii)
TW200407326A (en) Pyrimido compounds having antiproliferative activity
BR0317480A (pt) Derivados de piridino[2,3-d]pirimidina como inibidores kdr e fgfr seletivos
WO2002057261A3 (en) Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase
BRPI0511975A (pt) pirazolopirimidinas
JO2248B1 (en) Pirazolobenzodiazepines
IL191832A (en) Pyridiazinone compounds and their use in the preparation of drugs for the treatment of tumors
IL260127B (en) mek inhibitors and methods of using them
MXPA05007352A (es) Compuestos triciclicos inhibidores de proteina quinasa para mejorar la eficacia de agentes antineoplasicos y terapia de radiacion.
BR0308030A (pt) Derivados de 5-feniltiazol e uso como inibidores de pi3 cinase
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
BRPI0407834A (pt) composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
BRPI0821743B8 (pt) derivados de piridazinona, e seu uso
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
MX2021007833A (es) Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer.
CY1108061T1 (el) Παραγωγα κιναζολινης ως src αναστολεις κινασης τυροσινης
BR0011778A (pt) Tienopirimidinas
BR0310081A (pt) Diaminotiazóis úteis como inibidores seletivos de cdk4
ATE287886T1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer
EA200501233A1 (ru) 4-аминопиримидин-5-он
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
BRPI0520482A2 (pt) amidas do ácido 4-amino-tieno [3,2-c] piridina-7-carboxìlico
BRPI0510001A (pt) diaminotiazóis substituìdos na piperidina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.